Nintedanib Slows FVC Decline in Systemic Sclerosis-Related ILD |
Journal Updates
eMediNexus Coverage from: 
Nintedanib Slows FVC Decline in Systemic Sclerosis-Related ILD
eMediNexus,  22 May 2019
remove_red_eye 563 Views
#Internal Medicine #Pharmacist #Pulmonary Medicine

0 Read Comments                

The tyrosine kinase inhibitor nintedanib (Ofev) appeared to slow the progression of systemic sclerosis–associated interstitial lung disease, reported the phase III SENSCIS trial.

In the primary endpoint analysis, the adjusted annual rate of decrease in forced vital capacity (FVC) was 52.4 mL among patients assigned to nintedanib compared with 93.3 mL for patients on placebo (P=0.04), reported Oliver Distler, MD, of the University Hospital Zurich in Switzerland.

The 41.0 mL per-year difference (95% CI 2.9-79.0) between the two groups translated to a 44% reduction in the slope of lung function decline for these patients with interstitial lung disease, said Distler.

The study was published in the New England Journal of Medicine.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now